Which combination of medications is referred to as "triple therapy" for treating multiple myeloma?

The combination of medications referred to as "triple therapy" for treating multiple myeloma is Velcade, Revlimid, and Dexamethasone. This trio is commonly used because it effectively targets multiple pathways involved in the progression of multiple myeloma.

Velcade (bortezomib) is a proteasome inhibitor that helps to induce apoptosis in malignant plasma cells by disrupting the degradation of pro-apoptotic factors. Revlimid (lenalidomide) has immunomodulatory properties and also inhibits the growth of myeloma cells while enhancing the immune response. Dexamethasone is a corticosteroid that helps to reduce inflammation and has cytotoxic effects on certain cancer cells. The synergistic effect of these three medications can lead to improved response rates in patients with multiple myeloma, making this combination a cornerstone of treatment in a variety of clinical settings.

Other options listed do not represent the established "triple therapy" regimen specifically for multiple myeloma, as they either involve different targets or are used for other types of cancers or conditions.